Skip to main content

Table 2 RR of grade ≥3 adverse events in patients with advanced gastric cancer treated with angiogenesis inhibitors

From: Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis

Grade ≥3 adverse events

No. of trials

Events/total

RR (95 % CI)

P value

Analysis model

Treatment group

Control group

Decreased appetite

5

55/1095

60/973

0.86 (0.61, 1.22)

0.39

Fixed

Vomiting

5

62/1051

67/975

0.94 (0.48, 1.82)

0.84

Random

Anemia

8

118/1419

125/1161

0.91 (0.55, 1.50)

0.7

Random

Hypertension

6

105/1318

22/1066

2.85 (0.87–9.30)

0.08

Random

Hemorrhage

4

27/898

31/698

0.65 (0.39–1.09)

0.11

Fixed

Thromboembolic events

4

42/778

56/598

0.68 (0.46, 1.00)

0.05

Fixed

Proteinuria

5

147/1218

141/529

1.07 (0.76–1.34)

0.94

Fixed

GI perforation

3

12/985

2/496

4.1 (1.14–15.05)

0.03

Fixed

Neuropathy

3

30/318

27/312

1.11 (0.68–1.82)

0.67

Fixed

Diarrhea

7

60/1135

35/1044

1.66 (1.11, 2.50)

0.01

Fixed

Nausea

6

45/996

58/952

0.77 (0.53, 1.11)

0.16

Fixed

Fatigue

7

79/904

55/627

0.91 (0.44, 1.88)

0.75

Random

Leukopenia

6

83/797

45/665

1.23 (0.61, 2.48)

0.58

Random

Thrombocytopenia

5

33/797

16/665

1.74 (0.96, 3.12)

0.07

Fixed

Neutropenia

7

217/842

118/711

1.53 (0.99, 2.37)

0.06

Random

Hand-foot syndrome

4

51/711

14/569

2.83 (1.57, 5.11)

0.0005

Fixed

Electrolyte disturbance

3

23/662

26/574

0.8 (0.32–1.99)

0.63

Fixed

Pain

6

42/694

31/676

1.06 (0.30, 3.79)

0.93

Random

Liver damage

4

56/414

19.287

1.59 (1.01, 2.51)

0.04

Fixed

  1. RR risk ratios, GI gastrointestinal